Table 2 Mean and ± SEM sample data for the two centre cohorts used for the biomarker discovery and validation cohorts

Biomarker discovery cohort

Control n = 15

LBD n = 10

Gender (M:F)

5:10

6:4

Mean Age at Sampling (yrs ± SD)

61 ± 9.9

71.9 ± 4.3

Median disease duration (yrs ± SD)

n/a

3.4 ± 1.57

Mean Aβ42 levels (pg/ml ± SD)

905.41 ± 237

695.6 ± 330.7

Mean h-tau levels (pg/ml ± SD)

136.58 ± 162

523 ± 432

Mean p-tau181 levels (pg/ml ± SD)

19.33 ± 11.11

52 ± 39

Validation cohort

Control n = 15

LBD n = 17

PD n = 7

AD n = 16

Gender (M:F)

5:10

10:7

5:2

6:10

Mean Age at Sampling (yrs ± SD)

61 ± 9.9

72.1 ± 5.5

68.1 ± 3.4

78.1 ± 6.67

Median disease duration (yrs ± SD)

3.3 ± 1.9

4.1 ± 2.78

Mean Aβ42 levels (pg/ml ± SD)

905.41 ± 237

663.5 ± 268

886.4 ± 232

503.68 ± 165.88

Mean h-tau levels (pg/ml ± SD)

136.58 ± 162

679 ± 673

139 ± 93

733.77 ± 481.25

Mean p-tau levels (pg/ml ± SD)

19.33 ± 11.11

64.5 ± 48.8

26 ± 11

93.38 ± 31.55